Daniel R Bacon1, Princess Onuorah1, Alexander Murr1, Christopher A Wiesen2, Jonathan Oakes3, Brian D Thorp1, Adam M Zanation1, Charles S Ebert1, David Wohl4, Brent A Senior1, Adam J Kimple1,5. 1. Department of Otolaryngology/Head & Neck Surgery, University of North Carolina Chapel Hill, Chapel Hill, NC. 2. Odum Institute - University of North Carolina at Chapel Hill, Chapel Hill, NC. 3. Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC. 4. Department of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC. 5. Marsico Lung Institute, Chapel Hill, NC.
Abstract
BACKGROUND: Evidence regarding prevalence of COVID-19 related Olfactory dysfunction (OD) among ambulatory patients is highly variable due to heterogeneity in study population and measurement methods. Relatively few studies have longitudinally investigated OD in ambulatory patients with objective methods. METHODS: We performed a longitudinal study to investigate OD among COVID-19 ambulatory patients compared to symptomatic controls who test negative. Out of 81 patients enrolled, 45 COVID-19 positive patients and an age- and sex-matched symptomatic control group completed the BSIT and a questionnaire about smell, taste and nasal symptoms. These were repeated at 1 month for all COVID-19 positive patients, and again at 3 months for those who exhibited persistent OD. Analysis was performed by mixed-effects linear and logistic regression. RESULTS: 46.7% of COVID-19 patients compared to 3.8% of symptomatic controls exhibited OD at 1-week post diagnosis (p<0.001). At 1 month, 16.7%, (6 of 36), of COVID-19 patients had persistent OD. Mean improvement in BSIT score in COVID-19 patients between 1-week BSIT and 1 month follow-up was 2.0 (95% CI 1.00 - 3.00, p<0.001). OD did not correlate with nasal congestion (r= -0.25, 95% CI, -0.52 to 0.06, p=0.12). CONCLUSIONS: Ambulatory COVID-19 patients exhibited OD significantly more frequently than symptomatic controls. Most patients regained normal olfaction by 1 month. The BSIT is a simple validated and objective test to investigate the prevalence of OD in ambulatory patients. OD did not correlate with nasal congestion which suggests a congestion-independent mechanism of OD.
BACKGROUND: Evidence regarding prevalence of COVID-19 related Olfactory dysfunction (OD) among ambulatory patients is highly variable due to heterogeneity in study population and measurement methods. Relatively few studies have longitudinally investigated OD in ambulatory patients with objective methods. METHODS: We performed a longitudinal study to investigate OD among COVID-19 ambulatory patients compared to symptomatic controls who test negative. Out of 81 patients enrolled, 45 COVID-19 positive patients and an age- and sex-matched symptomatic control group completed the BSIT and a questionnaire about smell, taste and nasal symptoms. These were repeated at 1 month for all COVID-19 positive patients, and again at 3 months for those who exhibited persistent OD. Analysis was performed by mixed-effects linear and logistic regression. RESULTS: 46.7% of COVID-19 patients compared to 3.8% of symptomatic controls exhibited OD at 1-week post diagnosis (p<0.001). At 1 month, 16.7%, (6 of 36), of COVID-19 patients had persistent OD. Mean improvement in BSIT score in COVID-19 patients between 1-week BSIT and 1 month follow-up was 2.0 (95% CI 1.00 - 3.00, p<0.001). OD did not correlate with nasal congestion (r= -0.25, 95% CI, -0.52 to 0.06, p=0.12). CONCLUSIONS: Ambulatory COVID-19 patients exhibited OD significantly more frequently than symptomatic controls. Most patients regained normal olfaction by 1 month. The BSIT is a simple validated and objective test to investigate the prevalence of OD in ambulatory patients. OD did not correlate with nasal congestion which suggests a congestion-independent mechanism of OD.
Authors: Andreas Steenholt Niklassen; Julia Draf; Caroline Huart; Constantin Hintschich; Simone Bocksberger; Eleonora Maria Consiglia Trecca; Ludger Klimek; Serge D Le Bon; Aytug Altundag; Thomas Hummel Journal: Laryngoscope Date: 2021-01-15 Impact factor: 3.325
Authors: David H Brann; Tatsuya Tsukahara; Caleb Weinreb; Marcela Lipovsek; Koen Van den Berge; Boying Gong; Rebecca Chance; Iain C Macaulay; Hsin-Jung Chou; Russell B Fletcher; Diya Das; Kelly Street; Hector Roux de Bezieux; Yoon-Gi Choi; Davide Risso; Sandrine Dudoit; Elizabeth Purdom; Jonathan Mill; Ralph Abi Hachem; Hiroaki Matsunami; Darren W Logan; Bradley J Goldstein; Matthew S Grubb; John Ngai; Sandeep Robert Datta Journal: Sci Adv Date: 2020-07-24 Impact factor: 14.136
Authors: Renata Emmanuele Assunção Santos; Maria Giselda da Silva; Maria Caroline Barbosa do Monte Silva; Danielly Alves Mendes Barbosa; Ana Lisa do Vale Gomes; Ligia Cristina Monteiro Galindo; Raquel da Silva Aragão; Kelli Nogueira Ferraz-Pereira Journal: Am J Otolaryngol Date: 2021-01-06 Impact factor: 1.808
Authors: Carol H Yan; Farhoud Faraji; Divya P Prajapati; Christine E Boone; Adam S DeConde Journal: Int Forum Allergy Rhinol Date: 2020-06-01 Impact factor: 5.426
Authors: Marco A Lima; Marcus Tulius T Silva; Raquel V Oliveira; Cristiane N Soares; Crissi L Takano; Anna E Azevedo; Raissa L Moraes; Rafaela B Rezende; Ingrid T Chagas; Otávio Espíndola; Ana Claudia Leite; Abelardo Araujo Journal: J Neurol Sci Date: 2020-08-26 Impact factor: 3.181
Authors: Shima T Moein; Seyed MohammadReza Hashemian; Payam Tabarsi; Richard L Doty Journal: Int Forum Allergy Rhinol Date: 2020-08-19 Impact factor: 5.426